Navigation Links
The next era in discovering drugs in nature's own medicine cabinet
Date:9/4/2013

New technology for discovering antibiotics, anti-cancer drugs and other medicines inside soil microbes and other natural sources is reviving a treasure hunt that already has given humanity more than 50 percent of today's prescription drugs. This new era in "bioprospecting" is the topic of the cover story in Chemical & Engineering News, the weekly newsmagazine of the American Chemical Society.

Lisa M. Jarvis, C&EN senior editor, points out that natural products are the source of about half of the modern drugs approved in the U.S. But the search for new products slowed as drug companies learned to make synthetic compounds at high speeds by the thousands. Now, the increasing availability and affordability of DNA sequencing is reviving activity in the field. It enables scientists to sample the DNA of thousands of microbes at once in search of gene clusters that could yield a new drug. Then computer models can figure out what molecules the genes encode, and organize the information in searchable databases.

The potential for discovering new medicines is high enough to attract the attention and millions of dollars in investments of some of the pharmaceutical industry's major players, including Sanofi and Novartis. The article notes that the latest research has significantly increased the number of microbial compounds being discovered and has opened a window on a vast new library of genes and gene clusters that code for previously undiscovered drugs. The flood of genetic discovery underpins expectations that potential new medicines based on natural products will be in clinical trials in humans within a few years.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related biology news :

1. Researchers develop tools for discovering new species
2. Discovering cell surface proteins behavior
3. Drug design success propels efforts to fight HIV with a combination of 2 FDA-approved drugs
4. First update in a century in testing drugs for elemental impurities
5. New drugs to find the right target to fight Alzheimers disease
6. Alternative target for breast cancer drugs
7. Toward broad-spectrum antiviral drugs for common cold and other infections
8. Gene variants may predict who will benefit from breast cancer prevention drugs
9. New screening technique paves the way for protein drugs from bacteria
10. Soda and illegal drugs cause similar damage to teeth
11. A new strategy required in the search for Alzheimers drugs?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... features a variety of fracture-specific plating options designed to address fractures of the ... fracture fixation solutions. , The Acumed Ankle Plating System 3 is composed of ...
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of Athens say they ... may be hampering the research that could lead to one good one. Surviving Mesothelioma ... it now. , The team evaluated 98 mesothelioma patients who got ...
(Date:5/25/2016)... Haven, Connecticut (PRWEB) , ... May 25, 2016 ... ... that the U.S. Food and Drug Administration (FDA) has granted the company’s orphan ... is the company’s second orphan drug designation granted by the FDA. , ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an ... and entrepreneurs, held The Future of San Diego Life Science event at the Estancia ... science community attended the event with speakers Dr. Rich Heyman, former CEO of Aragon ...
Breaking Biology Technology: